Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

FTSE climbs for fourth straight week, shrugging off Trump slump

Published 19/05/2017, 17:11
© Reuters. People walk through the lobby of the London Stock Exchange in London
UK100
-
BARC
-
HIK
-
RIO
-
AAL
-
TCGI
-
SMIN
-
EXPN
-
SNR
-

By Helen Reid

LONDON (Reuters) - Britain's major share index recovered on Friday after a pullback in the previous session, notching up its fourth straight week of gains as investors focused on underlying earnings growth and better economic data.

The FTSE 100 (FTSE) was up nearly 0.5 percent on the day, bringing it into positive territory for the week after its performance was dented by worries over turmoil in U.S. President Donald Trump's administration that sent stocks tumbling across the globe.

Investors looked through the political uncertainty to a better earnings season and improved UK retail sales data which pointed to a brighter outlook for consumer-facing stocks.

"Generally earnings have been better than expected," said Laura Foll, head of the UK equity fund at Henderson.

"The retail sales data that came out yesterday was slightly higher than people were expecting, so there's also some relief after the March data which was quite weak."

Blue-chips hovered just below the fresh record high set on Tuesday.

While flows data shows investors have been piling into European equities, with a preference for the region accentuated since the French election, British stocks could be snubbed due to Brexit fears bubbling under the surface.

"The UK hasn't benefited from the inflows that Europe has," said Foll.

Miners Rio Tinto (L:RIO) and Anglo American (L:AAL) underpinned gains on the index, up 2.1 to 2.4 percent.

Hikma (L:HIK) shares recovered from early losses to end 2.5 percent higher, after the drugmaker trimmed its revenue forecast for the year to reflect the delayed launch of its generic drug Advair.

"Despite the ongoing difficulties in delivering the potential of its Roxane acquisition, we remain confident of Hikma's long-term potential, with generic Advair, first to file Zytiga and first to file Xyrem opportunities still to come," said Stifel analysts.

Hikma fell 8 percent last week after U.S. regulators denied approval for Advair, citing "major" issues with the application.

A broad-based recovery pushed the FTSE higher, but some stocks bucked the trend.

Engineering conglomerate Smiths (L:SMIN) fell 2.8 percent after its chief financial officer stepped down.

"The timing is poor: just as FX tailwinds recede and industrials come under some pressure, the uncertainty this creates does in the short term dent the safe haven status we believe some investors accord Smiths," Stifel analysts said.

The world's biggest credit data company, Experian (L:EXPN), fell 1.7 percent after Jefferies cut the stock to 'hold', citing slowing U.S. credit momentum.

Experian extended the previous session's losses, when allegations against Brazil's president roiled markets and sent it and other stocks exposed to the Latin American country down.

Among mid-caps, tour operator Thomas Cook Group (L:TCG) fell 2.9 percent after Barclays (LON:BARC) cut the stock to equal weight, citing a strong recent run, challenging market environment and concerns about the UK consumer.

© Reuters. People walk through the lobby of the London Stock Exchange in London

A 'strong buy' from broker Raymond James pushed engineering and defence firm Senior (L:SNR) up 6.5 percent, making it the top mid-cap gainer.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.